Sanofi Said to Value Genzyme at $20 Billion

Sanofi Said to Value Genzyme at $20 Billion

JB Reed/Bloomberg

A bottle of Genzyme Corp.'s chronic kidney disease treatment Hecterol is arranged for a photo at New London Pharmacy in New York.